Skip to main content

Table 3 Univariate and multivariate analyses of OS and BCSS for the MBC variables included in the study after PSM

From: The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database

Characteristics

Univariate

Multivariate

OS

BCSS

OS

BCSS

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Age at diagnosis (< 60 as ref.)

 ≥ 60

1.49 (1.20–1.85)

< 0.001

1 (0.78–1.289)

0.987

1.6 (1.26–2.05)

< 0.001

1.23 (0.94–1.62)

0.138

Race (white as ref.)

 Black

1.18 (0.89–1.60)

0.243

1.22 (0.89–1.68)

0.22

1.03 (0.77–1.39)

0.842

0.95 (0.68–1.32)

0.755

 Others

0.96 (0.61–1.49)

0.842

1.07 (0.66–1.73)

0.798

1.09 (0.69–1.71)

0.723

1.06 (0.65–1.74)

0.813

Marital status (single as ref.)

 Married

0.7 (0.53–0.94)

< 0.05

0.62 (0.46–0.84)

< 0.01

0.68 (0.50–0.91)

0.01

0.68 (0.49–0.95)

< 0.05

Grade (G1 as ref.)

 G2

0.98 (0.48–2.01)

0.958

0.8 (0.33–1.93)

0.617

0.96 (0.47–1.98)

0.918

0.8 (0.33–1.94)

0.62

 G3

1.58 (0.84–2.97)

0.155

1.8 (0.85–3.82)

0.127

1.23 (0.65–2.32)

0.529

1.26 (0.59–2.68)

0.557

 G4

1.34 (0.64–2.80)

0.439

1.58 (0.67–3.77)

0.299

1.34 (0.64–2.81)

0.443

1.44 (0.60–3.44)

0.411

ER status (negative as ref.)

 Positive

0.82 (0.60–1.14)

0.239

0.84 (0.59–1.21)

0.353

0.83 (0.57–1.21)

0.331

0.76 (0.50–1.15)

0.19

PR status (negative as ref.)

 Positive

0.63 (0.43–0.93)

< 0.05

0.77 (0.51–1.15)

0.204

0.67 (0.43–1.04)

0.074

0.89 (0.56–1.42)

0.627

Stage T (≤ 5 cm as ref.)

 > 5 cm

3.84 (3.08–4.78)

< 0.001

4.41 (3.44–5.66)

< 0.001

2.99 (2.31–3.86)

< 0.001

3.18 (2.39–4.24)

< 0.001

Stage N (N0 as ref.)

 N1

1.56 (1.20–2.05)

0.001

2.02 (1.51–2.71)

< 0.001

1.21 (0.91–1.61)

0.191

1.43 (1.04–1.95)

< 0.05

 N2

2.91 (2.02–4.20)

< 0.001

3.29 (2.19–4.95)

< 0.001

1.84 (1.24–2.72)

< 0.01

1.82 (1.17–2.82)

< 0.01

 N3

3.27 (2.14–5.00)

< 0.001

4.04 (2.55–6.40)

< 0.001

2.2 (1.39–3.48)

0.001

2.41 (1.46–3.98)

0.001

Breast operation (lumpectomy as ref.)

 Mastectomy

2.6 (2.04–3.31)

< 0.001

3.18 (2.38–4.25)

< 0.001

1.46 (1.08–1.98)

< 0.05

1.52 (1.06–2.18)

< 0.05

Chemotherapy (not done/unknown as ref.)

 Done

0.84 (0.67–1.05)

0.12

1.35 (1.02–1.80)

< 0.05

0.75 (0.58–1.00)

< 0.05

1.08 (0.79–1.48)

0.617

Radiotherapy (not done as ref.)

 Done

0.62 (0.50–0.77)

< 0.001

0.65 (0.51–0.84)

< 0.001

0.64 (0.51–0.80)

< 0.001

0.64 (0.50–0.83)

0.001

Axilla LN operation (SLNB as ref.)

 ALND

1.89 (1.49–2.39)

< 0.001

2.22 (1.68–2.92)

< 0.001

1.17 (0.89–1.54)

0.254

1.16 (0.85–1.60)

0.347

  1. SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection
  2. Significant results are in italic
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us